Ascendis Pharma A/S
ASND
$223.82
-$3.59-1.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 45.21% | -61.69% | 55.71% | -142.84% | 62.40% |
| Total Depreciation and Amortization | 7.37% | -3.90% | 2.22% | 11.95% | -11.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 79.84% | -49.95% | 199.70% | -58.78% | 237.75% |
| Change in Net Operating Assets | 61.05% | 158.00% | -193.97% | 143.36% | -235.62% |
| Cash from Operations | 3,294.47% | 130.21% | 44.69% | 83.79% | -50.59% |
| Capital Expenditure | -6,266.77% | 98.74% | -565.49% | -81.19% | 26.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -6,266.77% | 98.74% | -565.49% | -80.75% | 25.99% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -4.00% | -19.76% | -78.96% | -4.04% | -4.80% |
| Issuance of Common Stock | -66.21% | 264.33% | -9.87% | -38.03% | -92.47% |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -78.17% | 473.33% | 141.77% | -20,561.17% | -99.98% |
| Foreign Exchange rate Adjustments | -138.33% | 121.98% | -141.07% | -139.40% | 571.56% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 70.09% | 294.34% | 38.13% | 37.72% | -117.44% |